Reference

Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial

All Rights Reserved. Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial. Smith, Stacy R.In this study，68278-23-9 is also used.; Piacquadio, Daniel J.; Beger, Brian; Littler, Curt ( Therapeutics, Inc., San Diego, CA, USA). Dermatologic Surgery, 32(10), 1237-1243 (English) 2006 Blackwell Publishing, Inc. CODEN: DESUFE. ISSN: 1076-0512. DOCUMENT TYPE: Journal CA Section: 62 (Essential Oils and Cosmetics) Section cross-reference(s): 8, 63 Eflornithine cream is approved for the redn. of unwanted facial hair in women. The mechanism of action for eflornithine is redn. in follicular cell growth rate, while laser photoepilation heats hair and adjacent tissues to suspend growth. The objective was to assess the efficacy and safety of eflornithine or vehicle with laser therapy in the treatment of unwanted facial hair in women. Subjects were randomized to treatment with eflornithine on one side of the face and vehicle on the contralateral side for 34 wk. Subjects received Nd:YAG or alexandrite laser therapy to both sides of the face at Weeks 2 and 10. Blinded evaluations included left to right comparisons and appearance relative to baseline. Results Fifty-four women completed the trial. From Weeks 6 through 22, eflornithine-treated sides showed significant redn. in hair growth. By Week 34, no significant differences were seen. Subject grading showed significant and persistent hair redn. through Week 34 for eflornithine-treated sides. The safety profile for combination therapy is similar to eflornithine alone. Eflornithine is safely used in conjunction with laser hair removal treatments and promotes more rapid hair removal when combined with laser treatment. Patients demonstrate a clear preference for treatment with laser and eflornithine. .

Processes for the production of a-difluoromethyl ornithine (DFMO)

Some chemicals with cas registry numbers like 68278-23-9 are also used. Processes for the production of a-difluoromethyl ornithine (DFMO). Zhu, Jingyang; Chadwick, Scott T.; Price, Benjamin A.; Zhao, Shannon X.; Costello, Carrie A.; Vemishetti, Purushotham (Women First Healthcare, Inc., USA). PCT Int. Appl. WO 2003020209 A2 13 Mar 2003, 24 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K. APPLICATION: WO 2002-US26990 23 Aug 2002. 68278-23-9 is also in the experiment. PRIORITY: US 2001-PV315832 29 Aug 2001. DOCUMENT TYPE: Patent CA Section: 34 (Amino Acids, Peptides, and Proteins) Processes and synthetic intermediates for the prepn. of H2NCH2CH2CH2C(CHF2)(NH2)CO2H (DFMO) are described. Thus, condensation of glycine Et ester hydrochloride with benzaldehyde (MgSO4/Et3N/MeCN), addn. reaction with acrylonitrile (K2CO3/Et3N+CH2Ph Cl-), reaction with ClCHF2 (LiOBu-t/THF), and deprotection (4 N HCl/MTBE) yielded NCCH2CH2C(CHF2)(NH2)CO2H. Hydrogenolysis over 10% Pd/C in MTBE and treatment with 12 N HCl afforded DFMO.HCl (~ 75 % pure by 1H NMR). ..